期刊文献+

冠状动脉微血管功能障碍临床诊疗研究新进展

New Progress in Clinical Diagnosis and Treatment of Coronary Microvascular Dysfunction
下载PDF
导出
摘要 冠状动脉微血管功能障碍(Coronary Microvascular Dysfunction,CMD)是冠心病的一种特殊类型。冠状动脉微血管的功能或者结构异常会导致患者由于心肌缺血、缺氧引起心脏病,相关疾病涉及微血管心绞痛、心脏X综合征、冠脉慢血流现象等。患者临床症状以反复发作的心绞痛较为多见,随后可进展成急性冠脉综合征、缺血性心肌病或者心源性猝死等,若能够尽早提供合理有效的诊疗方式,可快速稳定患者病情,保障预后,提升生存质量。由此本文展开综述,探讨CMD的发病机制、临床特点以及可能的诊断和治疗策略,为后续临床诊治提供一定指导意义。 Coronary Microvascular Dysfunction(CMD)is a special type of coronary heart disease.It is because the abnormal function or structure of coronary microvessels leads to heart disease caused by myocardial ischemia and hypoxia.The related diseases involve microvascular angina,cardiac X syndrome,coronary slow blood flow phenomenon,etc.The clinical symptoms of patients are more common with recurrent angina pectoris,which can then develop into acute coronary syndrome,ischemic cardiomyopathy or sudden cardiac death,etc.If reasonable and effective diagnosis and treatment can be provided as soon as possible,the patients'condition can be stabilized rapidly,the prognosis can be guaranteed,and the quality of life can be improved.In this paper,the pathogenesis,clinical characteristics,possible diagnosis and treatment strategies of CMD were discussed to provide some guidance for subsequent clinical diagnosis and treatment.
作者 杨顺昱 YANG Shunyu(Guilin Hospital of Integrated Traditional Chinese and Western Medicine,Guilin,Guangxi 541004,China)
出处 《大医生》 2020年第20期118-120,共3页 Doctor
关键词 微血管性心绞痛 冠状动脉微血管功能障碍 诊断 治疗策略 microvascular angina coronary microvascular dysfunction diagnosis treatment strategies
  • 相关文献

参考文献7

二级参考文献62

  • 1张晋红,章国英.贝那普利与缬沙坦双重阻断肾素-血管紧张素系统对老年糖尿病肾病疗效的影响[J].中国老年学杂志,2014,34(4):890-891. 被引量:13
  • 2Piccolo R, Giustino G, Mehran R, et al. Stable coronary artery disease: revascularisation and invasive strategies [J].Lancet, 2015,386:702-713.
  • 3Kones R. Recent advances in the management of chronic stable angina I : approach to the patient, diagnosis, pathophysiology, risk stratification,and gender disparities [J]. Vasc Health Risk Manag ,2010,6:635-656.
  • 4Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery dis- ease: the Task Force on the management of stable coronary ar- tery disease of the European Society of Cardiology [ J ]. Eur Heart J ,2013,34:2949-3003.
  • 5Husted SE, Ohman EM. Pharmacological and emerging thera- pies in the treatment of chronic angina [ J ]. Lancet, 2015,386 : 691-701.
  • 6Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease:a report of the American College of Cardiology Foundation/A- merican Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Asso- ciation, Society for Cardiovascular Angiography and Interven- tions, and Society of Thoracic Surgeons [ J ]. J Am Coil Cardi- o1,2012,60 : e44-e164.
  • 7Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary ar- tery disease without clinical heart failure [ J ]. N Engl J Med, 2014,371 : 1091-1099.
  • 8Gupta AK, Winchester D, Pepine CJ. Antagonist molecules in the treatment of angina[ J]. Expert Opin Pharmacother,2013, 14:2323-2342.
  • 9Dzerve V,MILSS I Study Group. A dose-dependent improve- ment in exercise tolerance in patients with stable angina treated with mildronate : a clinical trial " MILSS I" [ J ]. Medicina (Kaunas) ,2011,47:544-551.
  • 10Povsic T J, Broderick S, Anstrom KJ, et al. Predictors of long- term clinical endpoints in patients with refractory angina[ J]. J Am Heart Assoc ,2015,4 : e001287.

共引文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部